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Abstract 
Purpose: To assess the anti-metastasis effects of thymol on human colorectal cancer cells. 
Methods: Human colorectal adenocarcinoma cell HT29 was incubated with varying concentrations of 
thymol. Cell viability, migration and invasion were determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-
dipheny-tetrazoliumbromide (MTT) and Transwell assays, respectively. Matrix metalloproteinase-2 and -
9 (MMP-2 and MMP-9) were analyzed by gel zymogram assay. Epithelial-mesenchymal transition 
(EMT)-associated gene expression and signaling pathway were analyzed using real-time quantitative 
polymerase chain reaction (PCR) and Western blotting, respectively. 
Results: Thymol was significantly inhibited migration and invasion of HT29 cell (p < 0.01) and also 
markedly reduced the activity of matrix degrading enzymes MMP-2 and MMP-9 (p < 0.01). Moreover, 
the epithelial marker, E-cadherin, was elevated, while mesenchymal markers (vimentin and α-SMA), 
and associated transcription factors (snail and slug) decreased after thymol treatment (p < 0.01). In 
addition, thymol inhibited the phosphorylation of PI3K/AKT and ERK pathways (p < 0.01). 
Conclusion: Thymol efficiently attenuates cell migration and invasion by decreasing EMT and 
downregulating the activation of PI3K/AKT and ERK signaling pathways in colorectal adenocarcinoma 
cells. It is, thus, a potential candidate drug for the management of colorectal cancer. 
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Colorectal cancer (CRC), one kind of the most 
digestive tract tumors, is the most common 
reason of cancer-related death, with between 
one and two million new cases diagnosed every 
year, and its incidence has been increasing year 
by year [1]. Modifiable risk factors for CRC 
related to lifestyle including smoking, physical 
activity habits, overweight, obesity and alcohol 
consumption. Chemotherapy and surgery are the 
most common treatment for CRC. CRC 
treatment has improved due to the application of 
a new generation of chemotherapy and 
-----------------------------------------------------------------------------------------------------------------------------------------------------
© 2017 The authors. This work is licensed under the Creative Commons Attribution 4.0 International License 
 
 
Lv & Chen 
2896 
 
molecular-targeted drugs, but it remains 
unsatisfactory. Moreover, the toxic side effects of 
chemotherapy drugs and the failure of 
chemotherapeutic due to drug resistance are 
some of the drawbacks of clinical treatment [2]. 
The treatment of metastasis is still not 
satisfactory, mainly due to lack of effective drugs 
[3]. Therefore, it is necessary to find new 
effective drugs to fight against metastasis for 
CRC. 
 
Thymol is an active monoterpene isolated from 
many medicinal herbs, such as Thymus vulgaris, 
Monarda punctate and Origanum vulgare spp [4]. 
It has been widely used for treatment 
inflammatory diseases, such as osteoarthritis [5] 
and asthma [6]. It reported that thymol has 
various bioactivities, such as anticancer [7], anti-
bacterial [8] and antioxidant properties [9]. 
Despite thymol being known for its multifaceted 
activities, the anti-metastatic ability on colorectal 
carcinoma cells has not been studied. 
 
The present study was designed to explore the 
effect of thymol on metastasis in human 
colorectal carcinoma cells. In view of its effects 
on the phosphorylation of PI3K/AKT and ERK 
pathways, the underlying mechanisms of how 
thymol inhibits cell migration and invasion, and 




Chemicals and reagents 
 
Thymol (C10H14O, MW: 150.22, purity ≥ 98 %) 
was purchased from Sigma (St. Louis, USA). It 
was dissolved in dimethylsulfoxide (DMSO) as 
stock solution of 10 M, stored at -20 °C, and 
freshly diluted with RPMI-1640 medium (Gibco, 
Carlsbad, CA) to the final concentration used in 
the study. [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
dipheny-tetrazoliumbromide] (MTT) was obtained 
from Sigma (St. Louis, USA). Antibodies against 
the following targets: AKT, phosphor-AKT, ERK, 
phosphor-ERK, and GAPDH were purchased 




The human colorectal adenocarcinoma HT29 cell 
(American Type Culture Collection, Bethesda, 
MD, USA) were cultured in RPMI1640 medium 
(Gibco, Carlsbad, CA, USA) supplemented with 
10 % fetal bovine serum (Gibco, Carlsbad, CA, 
USA), 100 U/mL penicillin and 100 mg/mL 
streptomycin. Cells were cultured under a 
humidified 5 % CO2 atmosphere at 37 °C.  
 
Cell viability assay 
 
Cell viability was measured using the colorimetric 
MTT assay as described previously [10,11]. The 
cells were cultured in 96-well plates overnight 
and treated with thymol (0.5, 1, 2, 4 mM) for 24 
and 48 h. Thereafter, cell viability was 
determined by MTT.  
 
Cell migration assay 
 
A Transwell assay was employed to determine 
cell migration [12]. HT29 cells (1 × 104 cells/well) 
was added into the upper chamber of the 
Transwell plates, and treated with thymol (0.5, 1 
and 2 mM), while the lower chamber contained 
600 μL culture medium with 10 % FBS. After 
treatment for 24 h, the cells that migrated to the 
bottom face of the membranes were stained with 
crystal violet solution and further extracted with 
10 % acetic acid. The absorbance at 540 nm 
represents the number of cells that migrated 
across the membrane.  
 
Cell invasion assay 
 
Cell invasive activity was performed by Matrigel 
assay [13]. Briefly, 5 × 104 cells were added to 
the chamber, and 100 μL Matrigel was added to 
the lower chamber. After incubation for 24 h, the 
cells were fixed with 4 % formaldehyde, stained 
with crystal violet and further extracted with 10 % 
acetic acid. The absorbance at 540 nm 
represents the number of cells that invaded 
across the Matrigel. 
 
Gelatin zymography assay  
 
The activity of MMP-2 and -9 were analyzed by 
using the gelatin zymography assay [14]. The 
HT29 cells were incubated with thymol (0.5, 1 
and 2 mM) for 24 h. The supernatants were 
separated by 10 % SDS-PAGE containing 1 % 
(m/v) gelatin. The gels were visualized after 





Cell lysates from HT29 cells were extracted in 
NP40 lysis buffer, separated by 10 % SDS-
PAGE gel and further transferred to PVDF 
membranes. The membranes were blocked with 
5 % nonfat milk for 2 h, and incubated with 
specific primary antibodies overnight at 4 °C, and 
then incubated with secondary antibody for 1 h at 
37 °C. The protein bands were visualized with 
ECL reagent (Millipore, Billerica, MA, USA). 
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Quantitative polymerase chain reaction 
(qPCR) assay 
 
Total RNA from HT29 cells was extracted with 
TRIzol according to the kit manufacturer’s 
instructions. RNA was transcribed to CDNA, 
which were analyzed for the expression of E-
cadherin, Vimentin, α-SMA, Snail and Slug by IQ 
SYBRGreen Supermix (Bio-Rad, Hercules, CA, 
USA). Primers were obtained from Sangon 
Biotech (Shanghai, China) and the details of the 




The data are given as mean ± SEM (n = 3). 
Differences between the groups were analyzed 
using SPSS software and one-way analysis of 
variance (ANOVA) followed by Dunnett's test. P 




Effect of thymol on viability in HT29 cells 
 
Firstly, we investigated the effect of thymol on 
cell viability at different concentrations (0.5, 1, 2 
and 4 mM). As shown in Figure 1, after treatment 
for 24 and 48 h, thymol markedly (4 mM) 
inhibited the cell viability in HT29 cells. 
Therefore, further studies were conducted using 
thymol (0.5, 1 and 2 mM) to avoid its cytotoxicity. 
 
Effect of thymol on cell migration 
 
To evaluate the anti-metastatic effect of thymol 
on HT29 cells, the migration of HT29 cells by 
Transwell assay was performed. As shown in 
Figure 2, thymol (1 and 2 mM) treatment led to 
an obvious decrease in HT29 cell migration 
across the membrane, compared to the control 
group. 
 
Effect of thymol on cell invasion 
 
HT29 cells were added into the upper chamber 
of Transwell insert pre-coated with Matrigel. After 
treatment with thymol (0.5, 1 and 2 mM) for 24 h, 
there was a concentration-dependent decrease 
on the invasion of HT29 cells, compared to the 
control (Figure 3). 
 
Effect of thymol on MMP-2 and MMP-9 
activities 
 
We evaluated the effects of thymol on 
extracellular matrix degradation catalyzed by 
MMPs with gelatin zymography assay. Figure 4 
showed that thymol (0.5, 1 and 2 mM) decreased 





Figure 1: Effect of thymol on the cell viability in HT29 
cells. HT29 cells were incubated with thymol (0.5, 1, 2, 
and 4 mM) for 24 and 48 h, and cell viability was 
examined by MTT assay. Data are expressed as 




Figure 2: Effect of thymol on cell migration. HT29 cells 
were incubated with thymol (0.5, 1 and 2 mM) for 24 h, 
and cell migration was analyzed by Transwell assay. 
Migrated cells were stained with Crystal violet and the 
numbers of migrated cells were determined by 
absorbance at 540 nm. Data are expressed as mean ± 
SEM (n = 3); *p < 0.05, **p < 0.01 vs control  
 
Table 1: Primer sequences of mouse used in 
real-time PCR 
 
Target gene Forward primer 5’-3’ Reverse primer 5’-3’ 
-cadherin GAGCCTGAGTCCTGCAGTCC GTATTGCTGCTTGGCCTCA 
Vimentin AAAGTGTGGCTGCCAAGAAC AGCCTCAGAGAGGTCAGCAA 
-SMA GGGTACCACCATGTACCCA CACAGTTGTGTGCTAGAGGC 
Snail CCCCAATCGGAAGCCTAACT CGTAGGGCTGCTGGAAGGTA 
Slug CCATTCCACGCCCAGCTA CTCACTCGCCCCAAAGATGA 
β-actin CCAACCGCGAGAAGATGA TCCATCACGATGCCAGTG 
 





Figure 3: Effect of thymol on cell invasion. HT29 cells 
were treated with thymol (0.5, 1 and 2 mM) for 24 h, 
and cell invasion was detected by Transwell assay. 
Invaded cells were stained with Crystal violet and the 
numbers of invaded cells were obtained by 
absorbance at 540 nm. Data are expressed as mean ± 




Figure 4: Effect of thymol on MMP-2 and MMP-9 
activities. HT29 cells were treated with thymol (0.5, 1 
and 2 mM) for 24 h. MMP-2 and MMP-9 on the 
degradation of gelatin were assessed. Data are 
expressed as mean ± SEM (n = 3); *p < 0.05, **: p < 
0.01 vs control 
 
Effect of thymol on epithelial-mesenchymal 
transition (EMT)  
 
Whether thymol plays important roles in EMT of 
colon cancer cells HT29, we analyzed the mRNA 
expression of major EMT biomarkers, including 
E-cadherin, Vimentin, α-SMA, Snail and Slug by 
using real-time PCR. As shown in Figure 5, 
thymol (2 mM) markedly increased the mRNA 
expression of E-cadherin, while decreased the 
mRNA expression of α-SMA, Vimentin, Snail and 
Slug. 
 
Effect of thymol on the PI3K/AKT and ERK 
pathway 
 
To find out whether the effect of thymol on HT-29 
cell invasion and migration involves PI3K/AKT or 
MAPK/ERK pathway, Western blot was 
performed to evaluate the protein levels of 
certain markers, including p-AKT and p-ERK. 
The results showed that thymol markedly 
decreased the phosphorylation levels of AKT and 
ERK, while it had no significant effect on the total 
levels of AKT and ERK in a concentration-
dependent manner (Figure 6). 
  
 
Figure 5: Effect of thymol on the mRNA expression of 
EMT-associated genes. HT29 cells were treated with 
thymol (0.5, 1 and 2 mM) for 24 h. Total RNA were 
extracted and the mRNA expression of E-cadherin, 
Vimentin, α-SMA, Snail and Slug were measured by 
real-time PCR assay. Gene expressions were 
normalized to β-actin. Data were expressed as means 
± SEM of three independent experiments *: P < 0.05, 




Metastasis is one of the major reasons of high 
mortality in CRC patients [15]. EMT, a process 
that tumor cell migrated and invaded from the 
surrounding tissue to the circulation, is 
characterized as the early step of the metastatic 
process [16]. Therefore, a compound that can 
effectively restrain cancer cell migration and 
invasion has the potential to be developed as a 
candidate drug for preventing or treating 
metastatic cancers. In this study, thymol 
significantly inhibited the migration and invasion 
in HT29 cells. It decreased the activity of MMP-2 
and MMP-9. The mechanisms may involve the 
inhibition of EMT and downregulation of the 
activation of PI3K/AKT and ERK signaling 
pathways. 
 
Invasion and migration have been acknowledged 
as the most lethal attributes of solid tumors and 
account for the majority of metastases [17]. 
Tumor cells have the ability to migrate from the 
original site to the blood and lymph, and invade 
surrounding or distant tissues, causing 
metastasis. Our results from the present study 
showed that thymol could suppress migration 
and invasion in HT29 cells.  
 
MMPs, a group of zinc-dependent 
endopeptidases, are important mediators of 
invasion and degradation of basement 
membranes and extracellular matrix [18]. MMP-2  





Figure 6: Effect of thymol on the activation of PI3K/AKT and ERK pathways. HT29 cells were treated with thymol 
(0.5, 1 and 2 mM) for 24 h. (A) Cells were harvested and lysed, and the levels of p-AKT, AKT, p-ERK, ERK and 
GAPDH were assessed by Western blot. (B) Densitometry analysis of immunoblotting was also shown. Data 
were presented as means ± SEM of three independent experiments *: P < 0.05, **: P < 0.01 vs control 
and MMP-9 abundantly expressed in various 
cancers, are considered to play key roles in 
tumor invasion and metastasis [19]. In addition, 
mounting evidence suggests that inhibition of 
MMP-9 and MMP-2 by chemopreventive agents 
suppresses the invasiveness and metastases of 
many cancer cells [20,21]. In the present study, 
thymol (1 and 2 mM) markedly reduced the 
activity of MMP-2 and MMP-9 in HT29 cells. 
 
Numerous studies have reported the correlation 
between EMT and cancer progression and 
metastasis [22]. Epithelial-derived tumor cells 
become malignant and obtain an invasive 
phenotype is mainly through an EMT process 
[23]. Several molecular markers, the down-
regulation of epithelial cell surface marker E-
cadherin, the up-regulation of mesenchymal 
markers vimentin and α-SMA, and the EMT-
inducing transcription factors such as Snail and 
Slug, are the representative phenotypes of EMT 
[24]. Our results revealed that thymol inhibited 
EMT, evidenced by increasing expression of E-
cadherin, decreasing the expression of vimentin 
and α-SMA, and associated transcription factors 
Snail and Slug. 
 
PI3K/AKT pathway overactivation is frequently 
present in CRC and is associated with tumor 
progression processes, including cell 
proliferation, migration and invasion [25]. It has 
been shown to contribute to tumor metastasis by 
promoting the secretion of MMPs and the 
induction of EMT [26]. It reported that MAPKs, 
such as ERK seem to play a central role in 
regulating the expression of MMPs, inhibition of 
the MAPK pathway might also potentially prevent 
invasion and metastasis of a variety of tumors 
[27]. The Western blotting results suggested that 
thymol could significantly inhibit the activation of 




This study has demonstrated that thymol is able 
to inhibit the migration and invasion of HT29 
human colon cancers, and reduce the activity of 
MMP-2 and MMP-9. The mechanisms may 
involve the inhibition of EMT and downregulation 
of the activation of PI3K/AKT and ERK signaling 
pathways. These results provided new insights 
into the anti-cancer mechanisms of thymol, which 
may be helpful in the development of thymol into 
a promising therapeutic agent against colorectal 
carcinoma. 
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